IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.545,48 +40,66 (+0,07%)
Starpharma Holdings Limited (SPL.AX)
Starpharma Holdings Limited
4-6 Southampton Crescent
Abbotsford, VIC 3067
Australia
61 3 8532 2700
https://starpharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 45
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Justin Cahill | CFO & Company Secretary | 127,7k | N/A | N/A |
| Ms. Cheryl Maley B.Sc., M.B.A. | CEO, MD & Director | N/A | N/A | 1969 |
Descripción
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
Gobierno corporativo
El ISS Governance QualityScore de Starpharma Holdings Limited, a día 1 de mayo de 2024, es 3. Las puntuaciones base son Auditoría: 6; Tablero: 4; Derechos de los accionistas: 1; Compensación: 5.
